O&G Vivas · Antenatal care — neurological disorders
Epilepsy in pregnancy — structured oral station (12 minutes)
FRANZCOG oral-format station on epilepsy in pregnancy: candidate counsels a woman of childbearing potential on valproate, defends the switch to lamotrigine or levetiracetam, addresses the EURAP evidence base, the lamotrigine clearance trap, folic acid, and the trade-off of seizure control vs AED teratogenicity. Scored against the eight published RANZCOG oral domains.
On this page & tools
Target exams
Station format
4 minutes reading, 12 minutes examination, 20 marks, global scoring. The eight published RANZCOG oral domains apply to every station: history and examination; investigations and interpreting results; treatment/management; clinical knowledge; complex, urgent or unusual clinical presentations; rapport with patient, support person or colleague; respect; communication skills. You are being marked on how you behave, not only what you know. [3]
Reveal the examiner script and model responses
Opening prompt — "Tell me your preconception advice to this woman."
Model response — say it in this order: [3][4]
- "I would start by acknowledging that this is a positive consultation — she is planning ahead, which is exactly what we want. My advice falls into three parts: switch off valproate, start folic acid 5 mg, and plan lamotrigine dose monitoring."[3][4]
- "Valproate is the most teratogenic antiepileptic drug — the EURAP 2018 Lancet Neurology study showed a major congenital malformation rate of 10.3 percent, compared with 2.9 percent for lamotrigine and 2.8 percent for levetiracetam. There is also a neurodevelopmental signal (autism, lower IQ)."[1]
- "I would recommend switching to lamotrigine or levetiracetam, done slowly under neurology supervision over the next 3 to 6 months so we maintain seizure control. We would not stop valproate abruptly — that risks status epilepticus."[3]
- "I would start folic acid 5 mg daily from today and continue through at least the first trimester."[4]
Examiner is listening for: the switch off valproate, the EURAP numbers, the slow switch under neurology, and folic acid 5 mg. [3]
Probe 1 — "She asks what happens if she gets pregnant on valproate before the switch is complete. Do you stop it?"
- "No. Stopping AEDs abruptly in pregnancy risks status epilepticus, which can be lethal to mother and fetus. EURAP 2016 showed that withdrawal of valproate in pregnancy approximately doubles the rate of generalised tonic-clonic seizures — 33 percent in the withdrawal group vs 16 percent in the maintained-therapy group."[5]
- "If she becomes pregnant on valproate, I would arrange an urgent MDT discussion with neurology about whether to continue at the lowest effective dose or to attempt a careful, supervised switch. The default is to continue with a dose reduction if seizure control allows."[3][5]
- "I would also offer a detailed anatomy scan at 18 to 20 weeks with a cardiac focus."[3]
Probe 2 — "She is now on lamotrigine and pregnant. What changes in pregnancy?"
- "Lamotrigine clearance rises 50 to 100 percent in pregnancy because of oestrogen-induced UGT1A4 glucuronidation. The Harden 2009 AAN practice parameter recommends monitoring lamotrigine levels in pregnancy (Level B)."[4]
- "I would check a baseline lamotrigine level now, repeat every trimester, and increase the dose empirically as clearance rises — often doubling by the third trimester. I would reduce the dose rapidly postpartum over 1 to 2 weeks to avoid toxicity as clearance falls."[4]
Probe 3 — "What is the trade-off you are managing?"
- "The trade-off is seizure control against AED teratogenicity. The framing sentence is: the harm of uncontrolled seizures exceeds the marginal benefit of stopping AEDs in pregnancy."[3]
- "Uncontrolled seizures risk trauma, hypoxia, status epilepticus, sudden unexpected death in epilepsy (SUDEP), and fetal harm. AEDs risk major congenital malformation and neurodevelopmental delay — most marked with valproate, much less with lamotrigine and levetiracetam."[1][3]
- "So we treat the mother to maintain seizure control with the safest effective drug at the lowest effective dose — usually lamotrigine or levetiracetam monotherapy."[3]
Probe 4 — "She is anxious about breastfeeding on lamotrigine. How do you counsel her?"
This is a scored domain, not a courtesy. Demonstrate it out loud: [4][6]
- Move to her eye level, use her name, acknowledge the worry.
- "Breastfeeding is encouraged on lamotrigine at standard doses. The NEAD study (Meador JAMA Pediatrics 2014) followed 181 children to age 6 and found no cognitive harm from breastfeeding on AEDs — in fact the breastfed children had a 4-point IQ advantage."[6]
- "Lamotrigine does pass into breast milk in small amounts. We monitor the baby for sedation, poor feeding or rash, but most do very well. We also recommend reducing your lamotrigine dose rapidly postpartum, which brings the baby's exposure down further."[4]
Probe 5 — "And contraception?"
- "Lamotrigine is not an enzyme inducer, so combined hormonal contraception is not affected by it in the way it would be by carbamazepine or phenytoin. However, combined oral contraceptives can lower lamotrigine levels, so we monitor."[4]
- "Progestogen-only methods (pill, implant, intrauterine system) are good options. If she is later switched to an enzyme-inducing AED, the combined oral contraceptive pill would be unreliable and we would recommend a higher-dose regimen or a non-hormonal method."[4]
You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Obstetrics & Gynaecology fellowship atlas.
References6Show ledgerHide ledger
- [1]Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry Lancet Neurol, 2018.PMID 29680205
- [2]Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study Neurology, 2015.PMID 26085607
- [3]Pack AM, Oskoui M, Williams Roberson S, Donley DK, French J, Gerard EE, Gloss D, Miller WR, Munger Clary HM, Osmundson SS, McFadden B, Parratt K, Pennell PB, Saade G, Smith DB, Sullivan K, Thomas SV, Tomson T, Dolan O'Brien M, Botchway-Doe K, Silsbee HM, Keezer MR Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM Neurology, 2024.PMID 38748979
- [4]Harden CL, Pennell PB, Koppel BS, et al. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society Neurology, 2009.PMID 19398680
- [5]Tomson T, Battino D, Bonizzoni E, et al. Withdrawal of valproic acid treatment during pregnancy and seizure outcome: Observations from EURAP Epilepsia, 2016.PMID 27319360
- [6]Meador KJ, Baker GA, Browning N, et al. Breastfeeding in children of women taking antiepileptic drugs: cognitive outcomes at age 6 years JAMA Pediatr, 2014.PMID 24934501